TerminatedPhase 3NCT02697136
CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases
Studying Apolipoprotein A-I deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cerenis Therapeutics, SA
- Principal Investigator
- Erik SG Stroes, MD PhDAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Intervention
- CER-001(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2018
Study locations (19)
- Investigative Site, Salt Lake City, Utah, United States
- Investigative Site, La Louvière, Belgium
- Investigative Site, Vancouver, British Columbia, Canada
- Investigative Site, Halifax, Nova Scotia, Canada
- Investigative Site, London, Ontario, Canada
- Investigative Site, Chicoutimi, Quebec, Canada
- Investigative Site, Montreal, Quebec, Canada
- Investigative Site, Lille, France
- Investigative Site, Montpellier, France
- Investigative Site, Rouen, France
- Investigative Site, Toulouse, France
- Investigative Site, Jerusalem, Israel
- Investigative Site, Tel Aviv, Israel
- Investigative Site, Genoa, Italy
- Investigative Site, Milan, Italy
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02697136 on ClinicalTrials.gov